# DefenCath (defencath) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/defencath

> The FDA approved DefenCath (defencath), sponsored by CorMedix Inc. (CRMD), on November 15, 2023 for kidney failure receiving chronic hemodialysis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is DefenCath (defencath) FDA approved?

Yes. The FDA approved DefenCath (defencath), sponsored by CorMedix Inc. (CRMD), on November 15, 2023 for kidney failure receiving chronic hemodialysis. Press release filed with the SEC (EX-99): "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." [Calendar and source filings](https://sec-api.dev/pdufa/defencath)

Source: Press release filed with the SEC (EX-99), accession 0001213900-25-072814, https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea025204301ex99-1_cormedix.htm (retrieved 2026-11-12). Last confirmed 2026-03-05. Cite: https://sec-api.dev/pdufa/defencath#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | DefenCath (defencath) |
| Codes |  |
| Sponsor | CorMedix Inc. (CRMD) https://sec-api.dev/companies/crmd/catalysts |
| Indications | kidney failure receiving chronic hemodialysis |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### November 15, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: kidney failure receiving chronic hemodialysis.
- First seen 2025-01-07, last confirmed 2026-03-05.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-072814): "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea025204301ex99-1_cormedix.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-059702): "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." https://www.sec.gov/Archives/edgar/data/1410098/000121390025059702/ea024745801ex99-1_cormedix.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-056415): "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." https://www.sec.gov/Archives/edgar/data/1410098/000121390025056415/ea024626101ex99-1_cormedix.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-039903): "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/ea024082701ex99-1_cormedix.htm
- Press release filed with the SEC (EX-99) (accession 0001013762-25-001844): "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/ea0235520ex99-1_cormedix.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-001392): "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/ea022695701ex99-1_cormedix.htm
- SEC Form 10-K (accession 0001213900-26-023889): "On November 15, 2023, we announced that the FDA approved the new drug application ("NDA") for DefenCath, an antimicrobial catheter lock solution ("CLS")" https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm
- SEC Form 10-Q (accession 0001213900-25-072843): "On November 15, 2023, we announced that the FDA approved the new drug application ("NDA") for DefenCath to reduce the incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC, DefenCath is indicated for use in a limited and specific population of patients." https://www.sec.gov/Archives/edgar/data/1410098/000121390025072843/ea0250361-10q_cormedix.htm
- SEC prospectus (424B) (accession 0001213900-25-059256): "On November 15, 2023, we announced that the FDA approved the new drug application ("NDA") for DefenCath to reduce the incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC, DefenCath is indicated for use in a limited and specific population of patients." https://www.sec.gov/Archives/edgar/data/1410098/000121390025059256/ea0247412-424b5_cormedixinc.htm
- SEC prospectus (424B) (accession 0001213900-25-059256): "November 15, 2023, we announced that the FDA approved the new drug application, ("NDA") for DefenCath to reduce the incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC." https://www.sec.gov/Archives/edgar/data/1410098/000121390025059256/ea0247412-424b5_cormedixinc.htm
- SEC prospectus (424B) (accession 0001213900-25-058406): "On November 15, 2023, we announced that the FDA approved the new drug application ("NDA") for DefenCath to reduce the incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC, DefenCath is indicated for use in a limited and specific population of patients." https://www.sec.gov/Archives/edgar/data/1410098/000121390025058406/ea0246889-424b5_cormedixinc.htm
- SEC prospectus (424B) (accession 0001213900-25-058406): "November 15, 2023, we announced that the FDA approved the new drug application, ("NDA") for DefenCath to reduce the incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC." https://www.sec.gov/Archives/edgar/data/1410098/000121390025058406/ea0246889-424b5_cormedixinc.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/defencath.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DefenCath (defencath) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/defencath

```bibtex
@misc{secapidev_pdufa_defencath_20261116,
  title        = {DefenCath (defencath) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/defencath}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_defencath_20261116","title":"DefenCath (defencath) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/defencath","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
